The effect of empagliflozin on proteinuria

Phase 3

Recruiting

• Conditions: Glomerulonephritis.; Glomerulonephritis; N05.9

• Registration Number: IRCT20090127001598N6
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Age more than 18 years old
Have at least 500 mg of proteinuria in 24-hour urine and glomerulonephritis and Have a stable condition in proteinuria during the last three months
Have eGFR=30 mL/min
Written consent to participate in the study
Do not use empagliflozin before entering the study
Absence of recurrent urinary tract infections
Pregnant and lactating patients are not entered in the study

Exclusion Criteria

Hypersensitivity reaction to empagliflozin
Unwillingness to continue cooperating in the study or not referring for further follow-up
Drug or dosage of drugs modification that may affect proteinuria (such as ACEI, ARB, aldosterone blockers, CNI, Mycophenolate, non-dihydropyridine calcium channel blockers)
Decreased patient's FBS less than 70 mg / dL during the study
Recurrent urinary tract infections

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proteinuria. Timepoint: Before starting the study and then three months later. Method of measurement: Measurement of protein in the patient's 24-hour urine.

Secondary Outcome Measures

Name	Time	Method
Improve kidney function. Timepoint: At the start and at the end of study. Method of measurement: Measurement of serum creatinine and calculation of eGFR.